The Latest Breaking News from DCGI

The Drug Controller General of India (DCGI) has asked all state drug regulators to withdraw AstraZeneca's anti-cancer drug Olaparib tablets. This drug which is mostly used for the treatment of patients with gBRCA mutation and advanced ovarian cancer and breast cancer has potential adverse effects, DCGI has said.

TMC researchers find resveratrol-copper combo reduces chemotherapy toxicity, may prevent cancer metastasis, and offer multiple health benefits.

India is on course to introduce regulations governing all the medical devices in the country on October 1, Drugs Controller General of India Rajeev Singh Raghuvanshi said at iPhex 2023

Intensivists and infectious diseases specialists, faced with a dire situation where effective antibiotics to treat drug-resistant infections are lacking, have called on the government to allow emergency use authorisation (EUA), as successfully done during the COVID-19 pandemic, for certain life-saving drugs.

DCGI calls for bridging bio-tech interface to get out of generic mindset

"The information from WHO that cough syrups manufactured by an Indian pharma company caused the death of 66 children due to the presence of ethylene glycol is alarming, Professor Y. K. Gupta, senior pharmacologist and vice-chairman of the Standing National Committee on Medicines said.

The Drugs Controller General of India (DCGI) has granted permission to send two lakh doses of the vaccine

Dilip Lunawat in his petition, "blamed the Government and others for misrepresenting the facts about the COVID-19 vaccine by making false claims about its safety and 'forcing' medical practitioners to take the vaccine. Read more on Dynamite News:

This the first time that a booster dose that is different from the one used for primary vaccination has been allowed in the country